Therapeutic use of psilocybin: Practical considerations for dosing and administration

被引:36
作者
MacCallum, Caroline A. [1 ]
Lo, Lindsay A. [2 ]
Pistawka, Carly A. [3 ]
Deol, Jagpaul Kaur [4 ]
机构
[1] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada
[2] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Publ Hlth Sci, Toronto, ON, Canada
[3] Univ British Columbia, Fac Sci, Vancouver, BC, Canada
[4] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源
FRONTIERS IN PSYCHIATRY | 2022年 / 13卷
关键词
psilocybin; psilocybin-assisted psychotherapy; psychedelics; psilocin; magic mushrooms; patient safety; 5-HT2A RECEPTOR FUNCTION; LIFE-THREATENING CANCER; PSYCHEDELIC DRUGS; PSYCHOACTIVE TRYPTAMINES; DEPRESSION; ANXIETY; ANTIDEPRESSANTS; GUIDELINES; INHIBITORS; LSD;
D O I
10.3389/fpsyt.2022.1040217
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals. This is particularly concerning given the medical complexity and vulnerable nature of patients for whom psilocybin-assisted psychotherapy may be considered. This article aims to provide health care professionals with an overview of practical considerations for psilocybin therapy, rooted in a patient safety focus. Within this piece we will review basic psilocybin pharmacology and pharmacokinetics, indications, practical therapeutic strategies (e.g., dosing, administration, monitoring) and safety considerations (e.g., contraindications, adverse events, and drug interactions). With this information, our goal is to increase the knowledge and comfort of health care professionals to discuss and counsel their patients on psilocybin therapy, ultimately improving patient care and safety.
引用
收藏
页数:8
相关论文
共 73 条
[21]  
City of Vancouver, 2021, Request for an exemption from the Controlled Drugs and Substances Act (CDSA) pursuant to section 561) that would decriminalize personal possession of illicit substances within the City of Vancouver
[22]   Recreational cannabis use impairs driving performance in the absence of acute intoxication [J].
Dahlgren, M. Kathryn ;
Sagar, Kelly A. ;
Smith, Rosemary T. ;
Lambros, Ashley M. ;
Kuppe, Madeline K. ;
Gruber, Staci A. .
DRUG AND ALCOHOL DEPENDENCE, 2020, 208
[23]   Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin [J].
Dahmane, Elyes ;
Hutson, Paul R. ;
Gobburu, Jogarao V. S. .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (01) :78-85
[24]   Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial [J].
Davis, Alan K. ;
Barrett, Frederick S. ;
May, Darrick G. ;
Cosimano, Mary P. ;
Sepeda, Nathan D. ;
Johnson, Matthew W. ;
Finan, Patrick H. ;
Griffiths, Roland R. .
JAMA PSYCHIATRY, 2021, 78 (05) :481-489
[25]   Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics [J].
de Vos, Cato M. H. ;
Mason, Natasha L. ;
Kuypers, Kim P. C. .
FRONTIERS IN PSYCHIATRY, 2021, 12
[26]   Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance [J].
Dinis-Oliveira, Ricardo Jorge .
DRUG METABOLISM REVIEWS, 2017, 49 (01) :84-91
[27]  
Gable RS, 2006, AM SCI, V94, P206, DOI 10.1511/2006.3.206
[28]   Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches [J].
Garcia-Romeu, Albert ;
Barrett, Frederick S. ;
Carbonaro, Theresa M. ;
Johnson, Matthew W. ;
Griffiths, Roland R. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (04) :353-361
[29]   Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression [J].
Gómez-Gil, E ;
Gastó, C ;
Carretero, M ;
Díaz-Ricart, M ;
Salamero, M ;
Navinés, R ;
Escolar, G .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (04) :251-258
[30]  
Government of Canada, 2022, SUBS 56 1 CLASS EX P